AQBioSim

Revolutionizing End-to-End Drug Discovery and Development with Large Quantitative Models (LQMs) 

We are redefining drug discovery with a comprehensive, end-to-end approach powered by Large Quantitative Models (LQMs) derived from AI and physics-based methods. From early-stage research to clinical candidate selection, our process accelerates the development of small molecules and biologics, delivering faster, more accurate solutions to the most challenging problems in drug discovery.

We offer a fully integrated solution that spans the entire drug discovery and development lifecycle, ensuring efficiency and precision at every stage.


We act as your strategic partner, seamlessly integrated into your programs to enhance your ability to generate novel molecular drug IP and clinical assets. Our focus is on optimizing and applying specialized LQM solutions tailored to your specific drug discovery and development needs, while ensuring they are broadly applicable and reusable in future projects, delivering long-term value.

Through a milestone-based project approach, SandboxAQ shares in the risk and incentives to deliver results that matter most to customers.

Accelerate Drug Discovery with AQBioSim

Connect with one of our experts and start your Quantitative AI journey today.

Talk to an expert

“My life’s work has been to investigate neurodegenerative diseases including Alzheimer's and Parkinson's disorders. As my colleagues and I are focused on treatments for these illnesses, I was looking for AI software that could speed up our development time and de-risk the drug candidate before clinical trials. We found SandboxAQ and their software has been transformative for our work. The SandboxAQ LQM for biopharma is an end-to-end solution which is speeding up our research as we move closer to the clinic.

Prior to SandboxAQ, we were only able to explore 250,000 compounds which yielded 25 hits over the course of a year. With SandboxAQ’s platform, we increased the chemical exploration space from 250,000 molecules to 5.6 million. We identified candidate molecules faster and more efficiently with a hit rate 30 times greater. As a scientist, I am deeply impressed with the technical depth and impact of SandboxAQ's AI technology.”

Dr. Stanley Prusiner, Nobel Laureate, UCSF

Use Cases

SandboxAQ’s generative chemistry AI designs optimized 3D drug molecules in minutes, transforming drug discovery by unlocking AI-generated therapeutics
SandboxAQ’s absolute free energy perturbation solution (AQFEP) revolutionizes drug discovery allowing massively fast & efficient AI-driven chemical space exploration

The SandboxAQ Braintrust

  • Tom Stephenson, Advisor with a focus on growth, technology and go-to-market
  • Joseph Lehár, PhD - Innovator, executive and advisor to biotechs, incubators, and funds
  • Eric Botto, Entrepreneur and board advisor
  • Dr. Emilio Gallicchio, Levy-Kosminsky Professor of Physical Chemistry at CUNY Brooklyn

Resources